BREAKWATER Trial Shows Encorafenib Triplet Significantly Improves Outcomes in First-Line BRAF V600E–Mutant mCRC

Treatment /

Top results from Cohort 3 of the Phase 3 BREAKWATER trial show that combining Braftovi (encorafenib), Erbitux (cetuximab), and FOLFIRI significantly improves outcomes for patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer. The study compared this targeted triplet with standard FOLFIRI chemotherapy with or without bevacizumab. The confirmed overall response rate was 64.4% with […]

BREAKWATER Trial Shows Encorafenib Triplet Significantly Improves Outcomes in First-Line BRAF V600E–Mutant mCRC Read More »

FDA Accepts Velexbru (Tirabrutinib) NDA for Relapsed/Refractory Primary CNS Lymphoma

Drug Approvals /

The U.S. Food and Drug Administration has accepted the New Drug Application for Velexbru (tirabrutinib), a BTK inhibitor, to treat relapsed or refractory primary central nervous system lymphoma (PCNSL). PCNSL is a rare and aggressive type of non-Hodgkin lymphoma that affects the brain and central nervous system. The application is based on results from the Phase

FDA Accepts Velexbru (Tirabrutinib) NDA for Relapsed/Refractory Primary CNS Lymphoma Read More »

FDA Approves Once-Monthly Rybrevant Faspro Plus Lazertinib for First-Line EGFR-Mutated NSCLC

Drug Approvals /

The U.S. Food and Drug Administration has approved a simpler once-monthly (every 4 weeks) dosing schedule for Rybrevant Faspro (subcutaneous amivantamab with hyaluronidase) combined with lazertinib as first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Patients can switch to the monthly schedule as early as Week 5, reducing the need for frequent clinic

FDA Approves Once-Monthly Rybrevant Faspro Plus Lazertinib for First-Line EGFR-Mutated NSCLC Read More »

Orca-T Plus Donor CAR T Therapy Shows 100% Remission in High-Risk B-ALL Trial

Treatment /

New results from a phase 1 trial (NCT05507827) show that combining Orca-T with donor-derived (allogeneic) CAR T-cell therapy may be a safe and highly effective treatment for high-risk B-cell acute lymphoblastic leukemia (B-ALL). Traditional CAR T therapy often does not produce long-lasting remissions and is frequently used as a bridge to transplant. Orca-T is a

Orca-T Plus Donor CAR T Therapy Shows 100% Remission in High-Risk B-ALL Trial Read More »

Scientists Identify N4BP2 as the Trigger Behind Chromosome Shattering in Cancer

Research Advances /

Researchers at the University of California, San Diego (UC San Diego) have discovered what triggers chromothripsis, a dramatic genetic event in which a chromosome breaks into many pieces and is stitched back together incorrectly. This process happens in about 25% of all cancers and in nearly all bone cancers. It can help tumors become resistant

Scientists Identify N4BP2 as the Trigger Behind Chromosome Shattering in Cancer Read More »

AI-Powered Nanotechnology Blood Test Detects Early Colorectal Cancer with 94% Accuracy

Diagnostics /

Colorectal cancer (CRC) can be cured if found early, but current screening tools like endoscopy and the CEA blood test often miss early-stage disease. Researchers have developed a new blood test called the SERS eCRC Metabolites Model (SCMM), which combines nanotechnology and artificial intelligence to detect tiny metabolic changes linked to early cancer. The team

AI-Powered Nanotechnology Blood Test Detects Early Colorectal Cancer with 94% Accuracy Read More »

Cytokine “Shield” Identified as Key Driver of Chemotherapy Resistance in Ovarian Cancer

Research Advances /

Ovarian cancer is the deadliest cancer of the female reproductive system. About 80% of patients relapse after initial chemotherapy, and most recurrent cases develop multidrug resistance. Standard treatment uses platinum-based drugs to damage DNA and paclitaxel to stop cell division, but cancer cells often adapt and survive. This resistance is largely driven by cytokines—signaling proteins

Cytokine “Shield” Identified as Key Driver of Chemotherapy Resistance in Ovarian Cancer Read More »

Nerve Signals Found to Drive Early Pancreatic Cancer Growth

Research Advances /

Researchers have found that the nervous system helps pancreatic cancer develop much earlier than scientists once believed, even before full tumors form. They discovered that certain support cells around early lesions, called myCAFs, send signals that attract nerve fibers. These nerves do not just appear later to help cancer spread—they are involved from the beginning

Nerve Signals Found to Drive Early Pancreatic Cancer Growth Read More »

Engineered Virus Turns “Cold” Glioblastoma Tumors “Hot,” Boosting Immune Attack

Treatment /

Researchers have shown that a genetically modified virus can help the immune system attack glioblastoma, one of the most aggressive brain cancers. The study was published in Cell. Glioblastoma is usually resistant to immunotherapy because it is considered an “immune cold” tumor, meaning immune cells do not easily enter or attack it. In this study,

Engineered Virus Turns “Cold” Glioblastoma Tumors “Hot,” Boosting Immune Attack Read More »

EGFR-Mutant Lung Cancer Treatment Shifts Toward Personalized Combination Strategies in 2026

Treatment /

Treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC) has moved beyond a single standard approach. In the past, most patients received osimertinib alone. Now, doctors choose between single-drug therapy and stronger combination treatments based on the patient’s condition and cancer behavior. Osimertinib (brand name Tagrisso) remains an important option, especially for patients with lower-risk

EGFR-Mutant Lung Cancer Treatment Shifts Toward Personalized Combination Strategies in 2026 Read More »